• Home
  • About IMWG
    • Mission
    • History
  • Publications
  • Summaries
  • Events
    • Annual Summit
    • Robert A. Kyle Lifetime Achievement Award
  • Multimedia
    • Conference Series
    • Photo Gallery
  • Home
  • About IMWG
    • Mission
    • History
  • Publications
  • Summaries
  • Events
    • Annual Summit
    • Robert A. Kyle Lifetime Achievement Award
  • Multimedia
    • Conference Series
      • ASH 2018 – San Diego
      • Stockholm 2018
      • ASH 2017 – Atlanta, GA
      • Madrid 2017
      • ASH 2016
      • Copenhagen 2016
      • ASH 2015
      • Vienna 2015
      • ASH 2014
      • Milan 2014
    • Photo Gallery

IMWG Guidelines for the Prevention of Thalidomide- and Lenalidomide-Associated Thrombosis in Myeloma

By imwgimf On April 20, 2010 · Add Comment · In Guidelines, Supportive Care
The risk of VTE in cancer patients is greater than 7%; those with myeloma have the highest risk of thrombosis.2 The oral immunomodulatory drugs, thalidomide and lenalidomide, further increase that risk. The following guidelines from the International Myeloma Working Group recommend a prophylaxis strategy based upon a risk assessment model. The recommendations have been made in the absence of clear data from randomized studies, and are therefore based on common sense and on data extrapolated from many studies not specifically designed to answer these questions. Treatment decisions must be based on the type of therapy and the patient’s individual risk factors. Risk factors for venous thromboembolism (VTE) in myeloma patients […]
Read More »

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

By imwgimf On August 27, 2009 · Add Comment · In IMWG Publications, Transplant
The past decade has witnessed a paradigm shift in the initial treatment of multiple myeloma with the introduction of novel agents such as thalidomide, lenalidomide, and bortezomib, leading to improved outcomes. High-dose therapy and autologous stem cell transplantation remains an important therapeutic option for patients with multiple myeloma eligible for the procedure. Before the advent of the novel agents, patients underwent stem cell collection prior to significant alkylating agent exposure, given its potential deleterious effect on stem cell collection. With increasing use of the novel agents in the upfront setting, several reports have emerged raising concerns about their impact on the ability to collect stem cells. An expert panel of […]
Read More »

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

By imwgimf On February 22, 2008 · Add Comment · In IMWG Publications, Supportive Care
The incidence of venous thromboembolism (VTE) is more than 1 per thousand annually in the general population and increases further in cancer patients. The risk of VTE is higher in multiple myeloma (MM) patients who receive thalidomide or lenalidomide, especially in combination with dexamethasone or chemotherapy. Various VTE prophylaxis strategies, such as low-molecular-weight heparin (LMWH), warfarin or aspirin, have been investigated in small, uncontrolled clinical studies. This manuscript summarizes the available evidence and recommends a prophylaxis strategy according to a risk-assessment model. Individual risk factors for thrombosis associated with thalidomide/lenalidomide-based therapy include age, history of VTE, central venous catheter, comorbidities (infections, diabetes, cardiac disease), immobilization, surgery and inherited thrombophilia. Myeloma-related […]
Read More »
 
  • Popular
  • Recent
  • Comments
  • Tags
  • Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaThe updated criteria for the diagnosis of myeloma represent a [...]
  • International Myeloma Working Group (IMWG) Criteria for the Diagnosis of Multiple Myeloma
  • IMWG Guidelines for the Prevention of Thalidomide- and Lenalidomide-Associated Thrombosis in Myeloma
  • Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working GroupWhole Body Low Dose CT (WBLDCT) has important advantages as [...]
  • Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American CountriesLatin American countries (LATAMC) represent a large fraction of patients [...]
  • Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working GroupFor decades conventional skeletal survey (CSS) has been the standard [...]
  • Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG studyIntroduction of new myeloma therapies offers new options for patients [...]
ASCT bone disease bortezomib classification computed tomography consensus cytogenetics diagnosis DVT genetic guidelines IMWG International myeloma working group International Staging System ISS lenalidomide magnetic resonance imaging molecular multiple myeloma myeloma patients prognosis response criteria stem cell survival thalidomide therapy thrombosis transplantation treatment
  • Categories

    • Diagnosis, Staging & Monitoring
    • Guidelines
    • IMWG Publications
    • Maintenance
    • Relapse
    • Supportive Care
    • Transplant
    • Treatment Options
  • Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
    To find out more, including how to control cookies, see here: Cookie Policy
  • Search

 
© 2019 IMWG